Manju George, PhD

Articles by Manju George, PhD

Which Treatment for Which Patient: Rectal Cancer Management After PROSPECT Trial

BySeth Felder, MD,Jessica Frakes, MD,Manju George, PhD,Allison Rosen, MS,Ibrahim Halil Sahin, MD

May 15th 2024

Determining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.

Latest Updated Articles

Which Treatment for Which Patient: Rectal Cancer Management After PROSPECT Trial
May 15th 2024

Trending on CancerNetwork

FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC

FDA Approves Vepdegestrant in ER+, HER2–, ESR1-Mutated Breast Cancer

FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer

Experts Analyze 6-Year Zanubrutinib Data Across CLL/SLL Settings

TIP137 ADELA: A Double-blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus Versus Elacestrant + Placebo in ER+/HER2- Advanced Breast Cancer (aBC) Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i